May 3, 2019
Seattle Genetics expands Adcetris indications in Canada
Health Canada hasapproved the supplemental New Drug Submission that expands the use ofADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin,vinblastine and dacarbazine) chemotherapy in patients with previouslyuntreated Stage IV Hodgkin lymphoma (HL).